Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Top Cited Papers
Open Access
- 9 February 2016
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 65 (5), 1190-1195
- https://doi.org/10.2337/db15-1356
Abstract
Pharmacologically induced glycosuria elicits adaptive responses in glucose homeostasis and hormone release. In type 2 diabetes (T2D), along with decrements in plasma glucose and insulin levels and increments in glucagon release, sodium–glucose cotransporter 2 (SGLT2) inhibitors induce stimulation of endogenous glucose production (EGP) and a suppression of tissue glucose disposal (TGD). We measured fasting and postmeal glucose fluxes in 25 subjects without diabetes using a double glucose tracer technique; in these subjects and in 66 previously reported patients with T2D, we also estimated lipolysis (from [2H5]glycerol turnover rate and circulating free fatty acids, glycerol, and triglycerides), lipid oxidation (LOx; by indirect calorimetry), and ketogenesis (from circulating β-hydroxybutyrate concentrations). In both groups, empagliflozin administration raised EGP, lowered TGD, and stimulated lipolysis, LOx, and ketogenesis. The pattern of glycosuria-induced changes was similar in subjects without diabetes and in those with T2D but quantitatively smaller in the former. With chronic (4 weeks) versus acute (first dose) drug administration, glucose flux responses were attenuated, whereas lipid responses were enhanced; in patients with T2D, fasting β-hydroxybutyrate levels rose from 246 ± 288 to 561 ± 596 µmol/L (P < 0.01). We conclude that by shunting substantial amounts of carbohydrate into urine, SGLT2-mediated glycosuria results in a progressive shift in fuel utilization toward fatty substrates. The associated hormonal milieu (lower insulin-to-glucagon ratio) favors glucose release and ketogenesis.Keywords
Funding Information
- Boehringer Ingelheim (U10-2392-01)
This publication has 17 references indexed in Scilit:
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretionNature Medicine, 2015
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsJCI Insight, 2014
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospectsNature Reviews Endocrinology, 2012
- Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patientsAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjectsAmerican Journal of Physiology-Endocrinology and Metabolism, 2002
- A circulatory model for calculating non-steady-state glucose fluxes. Validation and comparison with compartmental modelsComputer Methods and Programs in Biomedicine, 2002
- The theoretical bases of indirect calorimetry: A reviewMetabolism, 1988
- Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.JCI Insight, 1987
- Insulin within islets is a physiologic glucagon release inhibitor.JCI Insight, 1984
- Total body water volumes for adult males and females estimated from simple anthropometric measurementsThe American Journal of Clinical Nutrition, 1980